Dag Torfoss - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Dag Torfoss

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Journal of Thrombosis and Haemostasis : JTH|February 3, 2022

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-upTrine-Lise Larsen, Herish Garresori, Jorunn Brekke, et al.

Thrombosis Research|September 12, 2020

Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolismTrine-Lise Hannevik, Jorunn Brekke, Tone Enden, et al.

Thrombosis Research|June 16, 2023

Arterial events in cancer patients treated with apixaban for venous thrombosisTrine-Lise Larsen, Marte Svalastoga, Jorunn Brekke, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Journal of Thrombosis and Haemostasis : JTH|February 3, 2022

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients - 30 months follow-upTrine-Lise Larsen, Herish Garresori, Jorunn Brekke, et al.

Thrombosis Research|September 12, 2020

Thrombosis and bleedings in a cohort of cancer patients treated with apixaban for venous thromboembolismTrine-Lise Hannevik, Jorunn Brekke, Tone Enden, et al.

Thrombosis Research|June 16, 2023

Arterial events in cancer patients treated with apixaban for venous thrombosisTrine-Lise Larsen, Marte Svalastoga, Jorunn Brekke, et al.

Pageof 2